This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).
>98% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
ActiveMax® Human VEGF165, Tag Free (MALS verified) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
The purity of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is more than 95% in HP-SEC, and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.
Immobilized ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) at 0.1 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 1-10 ng/mL (QC tested).
Immobilized ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).
Avastin (Bevacizumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) with an affinity constant of 0.776 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Avastin (Bevacizumab) on AHC Biosensor, can bind ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) with an affinity constant of 0.016 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human NRP1, Fc Tag (Cat. No. NR1-H5252) on Protein A Biosensor, can bind Human VEGF165, Tag Free (Cat. No. VE5-H4210) with an affinity constant of 12.3 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human VEGF R1, His Tag (Cat. No. VE1-H5220) on HIS1K Biosensor, can bind ActiveMax® Human VEGF165, Tag Free (Cat. No. VE5-H4210) with an affinity constant of 43.4 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/mL (Routinely tested).
Inhibition assay shows that the proliferation effect of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).
Response to human VEGF165 protein (Fold). The VEGFR2 (Luc) HEK293 Reporter Cell (Cat. No. CHEK-ATF044) was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat. No. VE5-H4210). The max induction fold was approximately 70 (Routinely tested).
Authors: Chen PC, Hsueh YW, Lee YH, et al.
Journal: Cell Mol Life Sci 2020
Application: Flow cytometry
Authors: Stumpf C, et al
Journal: PLoS One 2020
Application: eBRET2 biosensors
Authors: ML Wetter, et al
Journal: US20180354997A1 2018
Authors: Keys TG, et al.
Journal: Metab Eng 2017
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $229.00
Price(USD) : $335.00
Price(USD) : $2300.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.